Boundless Bio, Inc.

Signal Note: Redmile Exit from Boundless Bio (BOLD)

Redmile's full exit from BOLD suggests loss of conviction despite RA Capital's continued backing—a divergence among specialist funds that typically exhibit high alignment on clinical-stage biotech. Without recent clinical catalysts or funding clarity, this exit likely reflects concern over cash runway or trial trajectory; given BOLD's pre-commercial stage, near-term dilution risk warrants monitoring if the company seeks capital before key data readouts.

Unlock full AI analysis — 14-day free trial